Clinical Trial Update: Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20) [Phase 3]

View source ↗

Summary

A Phase 3 randomized, double-blind study comparing two titration methods of the rivastigmine transdermal patch in Alzheimer's disease patients with MMSE 10-20 t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Rivastigmine Patch (Rivastigmine)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED | Results posted: 2015-05-12